PMID- 25677064
OWN - NLM
STAT- MEDLINE
DCOM- 20150528
LR  - 20220321
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 137
IP  - 1
DP  - 2015 Apr
TI  - The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
PG  - 173-9
LID - S0090-8258(15)00606-X [pii]
LID - 10.1016/j.ygyno.2015.02.003 [doi]
AB  - The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
      pathway plays a critical role in the malignant transformation of human tumors and 
      their subsequent growth, proliferation, and metastasis. Preclinical 
      investigations have suggested that the PI3K/AKT/mTOR pathway is frequently 
      activated in ovarian cancer, especially in clear cell carcinoma and endometrioid 
      adenocarcinoma. Thus, this pathway is regarded as an attractive candidate for 
      therapeutic interventions, and inhibitors targeting different components of this 
      pathway are in various stages of clinical development. Here, we highlight the 
      recent progress that has been made in our understanding of the PI3K/AKT/mTOR 
      pathway and discuss the potential of therapeutic agents that target this pathway 
      as treatments for ovarian cancer and the obstacles to their development.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Mabuchi, Seiji
AU  - Mabuchi S
AD  - Department of Obstetrics and Gynecology, Osaka University Graduate School of 
      Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address: 
      smabuchi@gyne.med.osaka-u.ac.jp.
FAU - Kuroda, Hiromasa
AU  - Kuroda H
AD  - Department of Obstetrics and Gynecology, Osaka University Graduate School of 
      Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Takahashi, Ryoko
AU  - Takahashi R
AD  - Department of Obstetrics and Gynecology, Osaka University Graduate School of 
      Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
FAU - Sasano, Tomoyuki
AU  - Sasano T
AD  - Department of Obstetrics and Gynecology, Osaka University Graduate School of 
      Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150210
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Ovarian Neoplasms/*drug therapy/*metabolism
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - *Phosphoinositide-3 Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-akt/*antagonists & inhibitors/genetics/metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/genetics/metabolism
OTO - NOTNLM
OT  - AKT
OT  - Ovarian cancer
OT  - PI3K
OT  - mTOR
OT  - mTORC1
OT  - mTORC2
EDAT- 2015/02/14 06:00
MHDA- 2015/05/29 06:00
CRDT- 2015/02/14 06:00
PHST- 2014/12/17 00:00 [received]
PHST- 2015/02/02 00:00 [accepted]
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/05/29 06:00 [medline]
AID - S0090-8258(15)00606-X [pii]
AID - 10.1016/j.ygyno.2015.02.003 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2015 Apr;137(1):173-9. doi: 10.1016/j.ygyno.2015.02.003. Epub 2015 
      Feb 10.